Oral anticoagulant accepted for NHS use after acute coronary syndromes

Rivaroxaban (Xarelto) has been accepted by NICE for preventing adverse outcomes after acute management of acute coronary syndromes.

Acute coronary syndromes include myocardial infarction (shown) and unstable angina. SCIENCE PHOTO LIBRARY
Acute coronary syndromes include myocardial infarction (shown) and unstable angina. SCIENCE PHOTO LIBRARY

In its latest technology appraisal of rivaroxaban, NICE recommends the direct oral factor Xa inhibitor as an option, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in people who have had an acute coronary syndrome and have elevated cardiac biomarkers.

Further information
NICE technology appraisal TA335

The risk of bleeding needs to be assessed before rivaroxaban is initiated and a decision on continuation of treatment should be taken after no more than 12 months.

Rivaroxaban has previously been accepted by NICE for the prevention of VTE after hip or knee replacement, the treatment and prevention of DVT and pulmonary embolism and the prevention of stroke in patients with atrial fibrillation.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases